INDV-2000 is under clinical development by Indivior and currently in Phase II for Opium (Opioid) Addiction. According to GlobalData, Phase II drugs for Opium (Opioid) Addiction have a 45% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how INDV-2000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

INDV-2000 overview

INDV-2000 is under development for the treatment of substance use disorder. The drug candidate is administered as either powder in solution or powder in capsule through oral route. The drug candidate acts by targeting orexin receptor type 1.
It was also under development for the treatment of panic disorders, anxiety disorders, and compulsive behaviors, nicotine addiction.

Indivior overview

Indivior develops, manufactures, and sells buprenorphine-based prescription pharmaceuticals for the treatment of opioid dependence. The company offers buprenorphine-based injectables for the treatment of opioid dependence, and buprenorphine-based injectable suspension, for subcutaneous use, for the treatment of schizophrenia. It also offers a nasal spray for the treatment of opioid overdose reversal. Its pipeline portfolio encompasses products for substance use disorder; and cannabis disorder. Indivior offers products in various formulations, including tablets, transmucosal films, nasal sprays, and injectables. It offers its products across various countries globally. Indivior is headquartered in North Chesterfield, Virginia, the US.

For a complete picture of INDV-2000’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.